Upstream Bio Announces $200M Series B Financing To Advance Upb-101 For Allergic And Inflammatory Diseases
Amount Raised
$200 Million
Round Type
Series B
WalthamBiotechnologyHealth CareScience And EngineeringInvestors
Description
Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the completion of a $200 million Series B financing. The Series B round was led jointly by Enavate Sciences and Venrock Healthcare Capital Partners, with participation from other new investors Bain Capital Life Sciences and Wellington Management and Series A investors OrbiMed, Access Biotechnology, Decheng Capital, Altshuler Shaham Provident Funds Ltd., TCG X, HBM Healthcare Investments, Omega Funds and Samsara BioCapital.
Quick answer
Upstream Bio raised $200 Million in a Series B round, dated June 8, 2023. Investors: Alex Rosen, Samsara Bio Capital, Omega Funds, HBM Healthcare Investments, Tcg X, Altshuler Shaham Provident Funds Ltd., Decheng Capital and Access Biotechnology. Upstream Bio is based in Waltham, Massachusetts, United States.
- How much did Upstream Bio raise?
- Upstream Bio raised $200 Million in a Series B round on June 8, 2023.
- Who invested in Upstream Bio?
- Alex Rosen, Samsara Bio Capital, Omega Funds, HBM Healthcare Investments, Tcg X, Altshuler Shaham Provident Funds Ltd., Decheng Capital and Access Biotechnology are named as investors in this round.
- What does Upstream Bio do?
- At Upstream Bio we strive to reach the source of inflammation and conquer it.
- Where is Upstream Bio based and how big is it?
- Upstream Bio is based in Waltham, Massachusetts, United States. Fundz records about 75 employees.
- Who are the decision-makers at Upstream Bio?
- Fundz holds 1 contact at Upstream Bio. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Upstream Bio that raised within 45 days of this round, from Fundz verified event records.
- RedHill Biopharma Ltd raised $2.7M (Seed) on July 21, 2023.
- Septerna raised $73M on June 28, 2023.
- Feldan Therapeutics raised $17M (Series B) on June 13, 2023.
- Ray Therapeutics raised $14M on May 15, 2023.
- Hubly raised $3M (Seed) on July 21, 2023.
- SURGE Therapeutics raised $32M (Series B) on July 19, 2023.
Who to call at Upstream Bio, and when
A new round usually means Upstream Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Upstream Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Upstream Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Upstream Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Upstream Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansUpstream Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.